Less than half of patients with the brain and spinal injury seen in multiple sclerosis (MS) are compliant with their treatment of disease-modifying drugs (DMDs), a study has shown.
Just 44 per cent of MS patients are taking the medication correctly after two years, according to research published in The Canadian Journal of Neurological Sciences.
DMDS are injected drugs which slow the progression of the condition and are known to decrease the incidence and severity of relapses.
Dr. Paul O'Connor, director of the MS Clinic at St Michael's Hospital, said: "There are a number of reasons why adherence to therapies of proven value might be low.
"These drugs don't work in everyone and some patients may stop them because they don't feel they are experiencing benefits. In some cases, patients may stop treatment because of side-effects."
This follows research at the University of Alberta which found that a potential MS treatment could be harmful to brain cells.
It was discovered that some T-cells, touted for use in MS therapies, could kill neurons in the brain.
News from Serious Law, specialist acquired brain injury solicitors
Posted by Matthew Dixon
